|
T13173 |
TMPA
|
|
Others
,
AMPK
|
|
TMPA is a nuclear receptor Nur77 and LKB1 interaction antagonist. |
|
T72282 |
Ebaresdax hydrochloride
|
|
Endogenous Metabolite
|
|
Ebaresdax hydrochloride has analgesic activity and is used in the study of painful diabetic neuropathy caused by type I or type II diabetes. |
|
T24905 |
TT01001
|
TT-01001,TT 01001,Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate |
Mitochondrial Metabolism
|
|
TT01001 (Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate) is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 c... |
|
T72617 |
Nampt activator-2
|
|
P450
,
NAMPT
|
|
Nampt activator-2 is a NAMPT activator (EC50: 0.023 μM). Nampt activator-2 has an affinity for CYP2C9, 2D6, and 2C19 with affinity values of 0.060 μM, 0.41 μM, and 0.59 μM, respectively.Nampt activator-2 can be used in t... |
|
T61483 |
GLP-1R modulator C5
|
|
Glucagon Receptor
|
|
GLP-1R modulator C5 is a small molecule GLP-1R orthosteric modulator that enhances GLP-1 binding to GLP-1R via transmembrane sites and can be used in the study of type II diabetes. |
|
T14176 |
Aleglitazar
|
RO0728804,R1439 |
PPAR
|
|
Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes. |
|
T78169 |
Enpp-1-IN-16
|
|
PDE
|
|
Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the ch... |
|
T7656 |
Apelin-13
|
|
|
|
Apelin-13 is a 13-amino acid peptide sequence found in the central and peripheral nervous system that is an endogenous ligand for the G protein-coupled receptor angiotensin II protein J (APJ), with an EC50 value of 0.37 ... |
|
T38683 |
SCD1 inhibitor-3
|
SCD1-IN-3,SCD1 inhibitor-3,SCD1 inhibitor 17a |
Dehydrogenase
|
|
SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety. SCD1 inhibitor-3 demonstrates strong potential for research in metabolic diseases, including obesit... |
|
T27598 |
Imigliptin Dihydrochloride
|
Imigliptin |
|
|
Imigliptin Dihydrochloride, a selective dipeptidyl peptidase IV (DPP-4) inhibitor, is used potentially for the treatment of type II diabetes. |
|
T71354 |
AMG-222 tosylate
|
|
|
|
AMG-222 tosylate is a DPP-IV inhibitor in clinical development for type II diabetes. |
|
T33598 |
Naveglitazar
|
LY 9818,LY-519818,LY519818,LY9818,LY-9818,LY 519818 |
|
|
Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes. |
|
T61124 |
α-Glucosidase-IN-9
|
|
|
|
α-Glucosidase-IN-9 (compound 7) is a highly potent α-glucosidase inhibitor with an IC50 of 55.6 μM, making it suitable for type II diabetes research [1]. |
|
T62994 |
α-Glucosidase-IN-10
|
|
|
|
α-Glucosidase-IN-10 (compound 13) is a potent inhibitor of α-glucosidase (IC50: 92.7 μM). α-Glucosidase-IN-10 can be used to study type II diabetes. |
|
T13497 |
3'-Hydroxy Repaglinide
|
|
Others
|
|
3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Repaglinide. Repaglinide is a carbamoylmethyl benzoic acid derivative and used as the treatment of type II diabetes. |
|
T38764 |
Amylin (8-37), human
|
|
|
|
Amylin (8-37), human, derived from human Amylin, possesses direct vasodilator effects in isolated mesenteric resistance arteries of rats. Human Amylin is a small pancreatic β-cell hormone that forms aggregates in the abs... |
|
T63739 |
PTP1B-IN-15
|
|
|
|
PTP1B-IN-15 is a potent and selective protein tyrosine phosphatase 1B (PTP1B) inhibitor that has shown research potential in type II diabetes and obesity. |
|
T64252 |
Efpeglenatide
|
|
|
|
Efpeglenatide is a long-acting agonist of the glucagon-like peptide (GLP-1) receptor. efpeglenatide improves insulin sensitivity and slows weight loss in mice models of diabetes and obesity. efpeglenatide has been used i... |
|
T40115 |
GAD65 (206-220)
|
GAD65 (206-220) |
|
|
GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a signif... |
|
T26868 |
BMS-986118
|
BMS 986118 |
|
|
BMS-986118 is a full agonist of GPR40, is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabete... |
|
T62576 |
Darglitazone Sodium
|
|
|
|
Darglitazone Sodium is a thiazolidinedione, a selective, orally active PPAR-γ (peroxisome proliferator-activated receptor) agonist, which can be used in the study of type II diabetes as it effectively controls glucose an... |
|
TP1183 |
Amylin, amide, human
|
DAP amide, human |
|
|
Amylin, a 37-amino acid polypeptide that is structurally related to calcitonin, is secreted from the B cells of the pancreas. Amylin has anoretic effects in rats. Amylin may be responsible for the etiology of insulin res... |
|
T79225 |
α-Amylase/α-Glucosidase-IN-3
|
|
Glucosidase
|
|
α-Amylase/α-Glucosidase-IN-3 (Compound 17) serves as a dual inhibitor targeting both α-Amylase and α-Glucosidase, exhibiting IC50 values of 0.70 μM and 1.10 μM, respectively. It is applicable for type-II diabetes mellitu... |
|
T68491 |
Melogliptin
|
|
|
|
Melogliptin, also known as EMD-675992 and GRC-8200, is a potent and selective a dipeptidyl peptidase IV (DPP-IV) inhibitor potentially for treatment of type II diabetes. Melogliptin significantly reduced HbA1c from b... |
|
T62019 |
Sheng Gelieting
|
|
|
|
Sheng Gelieting (CGT-8012) is a inhibitor of dipeptidy peptidase-IV enzyme (DP-IV) with an IC 50 value of 87 nM. Sheng Gelieting can be used for researching to the dipeptidy peptidase-IV enzyme, such as the diabetes, par... |
|
T63202 |
AP5 sodium
|
|
|
|
AP5 sodium is a selective, potent, orally active GPR40 receptor agonist that exhibits positive allosteric modulation of endogenous ligands (AgoPAM). sodium exhibits potential for the study of type II diabetes. |
|
T64189 |
NNMT-IN-3
|
|
|
|
NNMT-IN-3 (compound 14) is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT) with IC50 values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. nNMT-IN-3 can be used in stud... |
|
T79475 |
GPR119 agonist 2
|
|
|
|
GPR119 agonist 2 (compound 43), an orally active agonist of GPR119, exhibits favorable pharmacokinetic properties in rodents and has demonstrated efficacy in enhancing glucose tolerance in both mice and rats, indicating ... |
|
T72034 |
LI-2242
|
|
Others
|
|
LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the ... |
